Endologix LLC Announces Acquisition of PQ Bypass, Inc.
PQ Bypass’ proprietary Detour platform for percutaneous femoral-popliteal bypass has been designated by the U.S. Food & Drug Administration as a Breakthrough Device.
PQ Bypass’ proprietary Detour platform for percutaneous femoral-popliteal bypass has been designated by the U.S. Food & Drug Administration as a Breakthrough Device.
Copyright 2025 | All Rights Reserved | Medical Device News Magazine, is a Division of PTM Healthcare Marketing, Inc.